AI Summary
Accelerated epirubicin had worse quality of life (QOL) during treatment compared to standard epirubicin, while CMF had worse QOL effects than capecitabine for 24 months. Capecitabine showed favorable QOL compared to CMF, making it a suitable option after neoadjuvant chemotherapy for triple-negative breast cancer patients.
Accelerated epirubicin was associated with worse QOL than was standard epirubicin but only during treatment. These findings will help patients and clinicians make an informed choice about accelerated chemotherapy. CMF had worse QOL effects than did capecitabine, which were persistent for 24 months. The favourable capecitabine QOL compared with CMF supports its use as an adjuvant option after neoadjuvant chemotherapy in patients with triple-negative breast cancer.